Compare BridgeBio Pharma Inc (BBIO) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs T-Mobile Us Inc — how do they compare? BridgeBio Pharma Inc trades at $84.79 (market cap $16.36B), while T-Mobile Us Inc trades at $177.22 (market cap $191.56B). The key difference: T-Mobile Us Inc is far larger — about 11.7× BridgeBio Pharma Inc's market cap, and T-Mobile Us Inc pays a 2.28% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | TMUS | |
|---|---|---|
Market Cap | $16.36B | $191.56B |
Sector | Health | Media |
52-Week High | $90.17 | $259.01 |
52-Week Low | $47.29 | $167.65 |
Enterprise Value | $18.14B | $308.17B |
Dividend Yield | — | 2.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.67, up 0.22% today, with a bullish technical signal and strong analyst consensus. Despite missing Q2 2026 EPS estimates with a loss of $0.78 per share, revenue beat expectations as Attruby sales surged 311% year-over-year. The company maintains a high gross margin of 94.44% but reports negative net income and cash flow from operations, reflecting its growth investment phase.
The outlook is optimistic due to multiple late-stage pipeline catalysts, including three potential product launches by mid-2027 and an FDA decision on encaleret by May 2027. Risks include sustained cash burn, high debt of $1.72 billion, and clinical trial execution. The consensus price target of $104.56 implies significant upside if commercial execution succeeds.
T-Mobile US (TMUS) trades at $178.16, up 0.55% with neutral technical signals. The stock shows strong fundamentals with revenue growth from $81.4B in 2024 to $88.3B in 2025 and robust profitability (net margin 11.45%). Recent Q2 2026 earnings beat expectations with $2.99 EPS versus $2.59 estimate. The company completed a $2.9B spectrum sale to Grain Management in August 2026, enhancing cash position. Analyst consensus remains strongly bullish with 44 buy ratings and $233.20 price target, representing 31% upside potential.
TMUS presents compelling growth prospects with expanding broadband momentum and consistent earnings beats, though faces competitive pressure from SpaceX's Starlink mobile ambitions. The stock trades at reasonable valuations (P/E 18.68, EV/EBITDA 9.55) with strong institutional support. Key risks include wireless market saturation and technological disruption from new entrants. Current levels offer attractive entry point for long-term investors given the significant analyst upside and dividend growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
